LFA Statement on the Administration's Expected International Pricing Index Model
The Lupus Foundation of America supports efforts to lower patient out of pocket costs in Medicare Part B, which provides people with lupus access to the only drug approved to treat the disease. However, we are deeply concerned about the Administration’s plans to move forward with an International Pricing Index model which would base prices of Part B drugs on the cost of those drugs in certain foreign countries. Such a proposal may lead to significant unintended consequences that could limit patient access to current and future therapies. As details emerge, the Foundation will continue to work to ensure people with lupus who rely on Medicare Part B have access to the therapies they need to fight this disease.
Click here to read our comments on the Administration's 2018 proposed rule to implement an International Pricing Index model.